Today's Date: February 3, 2023
Urban One Inc's Reach Media Announces R&B Superstar Ralph Tresvant of New Edition as Host of "Love and R&B"   •   Conemaugh Miners Medical Center and Conemaugh Meyersdale Medical Center Achieve Designation as Lifepoint Health National Quality   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)   •   Government of Canada to support clean air and local economic growth by powering federal operations in Alberta and Saskatchewan w   •   Scottsdale Tesla Drivers Club and PS Academy Arizona Work Together on Tesla Cybertruck Build   •   Introduction of Diagnostic and Supplemental Imaging Legislation Would Benefit Thousands of Marylanders   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Honda Motor Co., Ltd. with Losses of $100,000 to Contact t   •   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behal   •   US Fertility founding partner Shady Grove Fertility (SGF) announces Egg Freezing for Surgical Residents Program in celebration o   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NE   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of National Vision Ho   •   Experiences of Black Women With Breast Cancer Highlight Need for Better Care, Improved Outcomes   •   General Dynamics Elects Richard Clarke to Board of Directors   •   TWO PUBLIC ALLIES ALUMNI JOIN THE NATIONAL BOARD OF DIRECTORS   •   Hyundai and TEN Advertising Develop Their First Asian American Campaign "My Love, My Son-in-Law" for the Tucson SUV   •   American Marketing Association San Diego Launches New Sandie Awards and Opens Call for Entries   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/   •   RESIDES CEO COLETTE STEVENSON NAMED 2023 RISMEDIA REAL ESTATE NEWSMAKER   •   Worldwide Shipments of Tablets and Chromebooks Declined Sharply in 2022, According to IDC Tracker   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Affirm Holdings, Inc.
Bookmark and Share

Generate Biomedicines Demonstrates a Novel Method of Reducing Immunogenicity through Protein Re-surfacing

CAMBRIDGE, Mass. , December 07 /Businesswire/ - Generate Biomedicines today announced that it has published data in the peer-reviewed journal Frontiers in Immunology that demonstrate the power of the company’s technology platform to generate re-surfaced proteins, which may provide a means to creating novel therapies for diseases with limited therapeutic options.

The study showed that the company’s approach to computational protein design was able to generate highly engineered E. coli L-Asparaginase (ASN) variants that maintain enzymatic function while significantly reducing binding to anti-drug antibodies and alleviating hypersensitivity responses in an animal model. By re-surfacing proteins, Generate may be able to reduce the effects of pre-existing immunity to protein-based therapies.

“Proteins are the machines of biology – the motors, the sensors – that make everything go. We are now engineering these machines to drive a desired biological task, potentially to treat a host of diseases,” noted Mike Nally, Generate’s Chief Executive Officer. “These data are further testament to the value of our integrated machine learning and wet-lab approach. This study highlights the potential of protein design in creating novel therapeutics and is part of our effort to design therapeutics with reduced immune response.”

“The optimal use of many biotherapeutics is restricted by anti-drug antibodies and hypersensitivity responses, which can affect potency and the ability to administer treatment for patients in need. Our ability to re-surface proteins represents an approach to help prevent the negative effects of anti-drug antibodies; we believe the resurfacing approach will be generalizable and may facilitate the development of new treatments for which additional options are urgently needed,” commented Alex Snyder, M.D., Generate’s Chief Medical Officer.

In the past, protein engineering has been costly as well as time- and labor-intensive and had limited capacity. The efficient and effective computational design of therapeutic proteins in this study has recently become feasible due to simultaneous innovations in computational processing power, machine learning approaches, and high-throughput methods for producing and evaluating novel proteins.

Previous attempts to modify ASN using traditional approaches resulted in mutants with up to eight modifications, according to a 2014 article in The Journal of Biological Chemistry. In this study, however, the authors demonstrate the generation of functional ASNs with up to 58 mutations. These high levels of mutations represent a significant advancement in our ability to design complex proteins to meet multiple objectives, such as maintenance of function and reduction in immunogenicity.

Because protein re-surfacing has many potential applications in oncology, ASN, used in standard-of-care regimens for Acute Lymphoblastic Leukemia (ALL), was selected as a clinically relevant biotherapeutic. Its use is critical to achieving an optimal clinical response, but is often limited due to the body’s immune response against it in the form of anti-drug antibodies (ADAs). Generate partnered with researchers at Dana-Farber Cancer Institute to assess the impact of re-surfacing on ADAs from ALL patients and demonstrated significantly reduced binding. This re-surfacing approach could be used to develop other novel protein treatment options for proteins hindered by these unwanted immune responses in patients.

About Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company’s platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting or following the company on Twitter and LinkedIn.

STORY TAGS: Product/Service, United States, North America, Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Massachusetts,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News